Penile enlargement without
surgery with the Andropenis
Device
Scientific Research presented in the
1st Virtual Sexology and Hispanoamerican Sexual
Education Congress (February -2001) Dr.
Eduardo A. Gomez de Diego „ 1998 Andrology
Services ,Andromedical Clinic, Madrid
(Spain)
1. Introduction:
When the human
tissues are submitted to a force of traction,
they react by increasing in size.
The
principle of traction is applied in modern
medicine, for the generation of new tissue to
cover burn wounds or areas of hair loss (
placing a tissular expander underneath the
normal skin ) or for the lengthening of
bones.
In other cultures this principle
is applied to lengthen different parts of the
body like the Giraffe Women of the Paduang tribe
in Birmania ; or the lengthening of the lips in
certain African tribes of Africa that use wood
to create traction; and in India where they hang
stones on the penis of men as a form of
penitence with the resulting enlargement of the
organ.
Based on this principle of
external traction the Andropenis® was
designed . It is able to exhort a gradual
traction force of 600 to 1500 grams.
The
device consists of a plastic ring, where the
penis is introduced and from where 2 dynamic
metalic rods that originate the traction. In the
superior part there is a plastic support where a
silicone band holds the glans in place.
Based on our
clinical experience the traction device yields
the following results:
- An increase in the length of the penis in
erection and flaccidity.
- An increase in the perimeter of the penis in
erection and flaccidity.
- This results will be analyzed statistically
to be verified and
quantified
2. Materials and
Methods
Number of patients: 37 patients,
ages between 22 and 60 years of age. These men
proceed from different cities in Spain.
Selection of patients: patients
included were healthy men with normal erection
capabilities and without penile surgeries.
Patients with penile or other diseases where
excluded from the studies.
Traction device: The
Andropenis®,
Spanish penile traction device.
Traction Force: 600 gr
during 1st month, 900 gr during 2nd month, 1100
gr durante 3th and 4th mes, and 1200 gr during
5th y 6th month.
Usage period: 10 hours a day,
during every day of the month for a period of
3-6 months.
3.
Results
3.1.- INCREASE IN LENGTH
IN ERECTION:
The average increase in the
length of the penis in erection by month is of
0.4726 cm. The standard deviation is of 0.1329
cm. The confidential interval of 95% is of
[0.4283 ; 0.5169] which indicates a minimal gain
in the population of 0.4283 cm/month.
Regression line is:
DL
erec = - 0.327 + 0.562 x t
This
calculation will allow us to estimate the
increase in length of the penis in erection,
based on the months of use of the device. There
is a 57.7% variance in the increment in
longitude, which is explained by the variance in
the duration of treatment ( R2= 0.577 ). The
other 42.3% is due to other differences innate
to each individual and not relative to the
duration of the treatment
3.2.- INCREMENT IN LENGTH
IN THE FLACCID STATE
The increment in length in the
flaccid state is relative to the time of usage
of the device. Such an increment is linear as
shown in the graph. The longer the device is
used, the greater the increase in length. The
coefficient of the linear correlation between
the time of usage and the increment in longitude
in the flaccid state is of 0.725 ( p=0.000 ).
The average monthly increment in
longitude of the penis in the flaccid state is
0.4834 cm and the typical deviation is 0.1983
cm. The confidence interval of 95% is of [0.4173
; 0.5495] and indicates a minimum increase in
the population of 0.4173 cm/month.
Regression line is:
DL
flac = - 1.300 + 0.840 x t
This
calculation allows us to estimate the increment
in longitude in the flaccid state based on the
months in which the device is used. There is a
52.5% variance in the increment in longitud
which is explained by the variance of the
duration of treatment ( R2= 0.525 ). The other
47.5% is due to other differences innates to the
individual and not relative to the duration of
the treatment.
3.3.-
VARIABILITY:
The variability in the increment
in longitude in erection is different from that
of flaccidity, being the difference in variance
significant ( p= 0.003 ) which indicates a
greater dispersion of the increases in length
during flaccidity than in erection.
3.4.- THE INCREMENT IN
LONGITUDE DOES NOT DEPEND ON THE AGE:
A very interesting result was
that the increment in longitude does not depend
on the age of the patient, since the coefficient
of the linear correlation is not significant (
r=0.008, p=0.961). In other words, the age of
the patient does not effect the increment in
longitude.
-
-
-
-
3.7.- LONGITUDE INCREASE
IN ERECTION STATE DEPENDING ON USE:
Dividing the population studied
in four sub groups depending on the usage time
of the Andropenis. we
obtain the following results.
Three months
usage: The median longitude increment
in erection state was 1.4118, obtaining a median
growth of 10.5580% over the initial longitude.
The confidence interval of 95% of the studied
population was ( 1.1522; 1.6713) which shows a
median minimal growth of 1.1522 cm in three
months.
Four months
usage: The median longitude increment
in erection state was 1.8462, obtaining a median
growth of 14.1113% over the initial longitude.
The confidence interval of 95% of the studied
population was(1.5809; 2.1114) which shows a
median minimal growth of 1.5809 cm in four
months.
Five months
usage: The median longitude increment
in erection state was 2.2750, obtaining a median
growth of 16.6303% over the initial longitude.
The confidence interval of 95% of the population
studied was (1.7656; 2.7844) which shows a
median minimal growth of 1.7656 cm in four
months.
Six months
usage: The median longitude increment
in erection state was 3.3333, obtaining a median
growth of 27.5% over the initial longitude. The
confidential interval of 95% of the population
studied was (2.8162; 3.8504) which shows a
median minimal growth of 2.8162 cm in six
months. The samples corresponding to five and
six months are very small which makes small
intervals and less reliable.
3.8.-
DISTRIBUTION:
Although the variables considered
in the population are not normal, the median
samples, have normal distribution since the
amount of the sample is greater than 20.
3.9.-
ABBREVIATIONS:
Inc-Long-Erec |
Longitude
increment in erection
state |
DL
erec |
Change in
Longitude increment in erection
state |
I.L.ERT |
Longitude
increment in erection as a function of the time
variable |
I.L.FLAC |
Longitude
increment in flaccid
state |
DL
flac |
Change in
Longitude increment in flaccid
state |
I.L.FLT |
Longitude
increment in flaccid state in function of
time |
Inc-Long-Erec |
Longitude
increment in erection
state |
% I
Long-Erec |
Longitude
increment percentage in erection
state. |
4.
Conclusions
The use of the Spanish traction
device (Andropenis ) will
increase the length of the penis, both in the
erectile and flaccid state.
The increase in length, both in
and flaccidity, is directly proportional to the
time of use.
The increase in length both in
erection and flaccidity, does not depend on the
natural size of the patient.
The average growth in length of
the penis in cm/month in 95% of the patients was
between 0.4283 and 0.5163 in erection, and
between 0.4173 and 0.5495 in flaccidity.
The increments of change in
length of the penis in erection are more uniform
than those in flaccidity which tend to be more
disparate .
The increment of change in the
length of the penis in erection is not relative
to the age of the patient.
The use of the penile traction
device will increase the perimeter of the penis,
both in erection and flaccidity.
The average growth in perimeter
in cm/month in 95% of the patients was between
0.6111 and 1.0200 in erection, and between
0.6386 and 1.0425 in flaccidity. Treatment was
3-6 months duration.
5. Anex
PATIENT RESULTS (Using
the
Andropenis):
Nombre
|
Edad |
Inicio |
L-Erec1 |
L-Flac1 |
P-Erec1 |
P-Flac1 |
Meses |
L-Erec2 |
L-Flac2 |
P-Erec2 |
P-Flac2 |
LAA |
60 |
15.1.98 |
12.0 |
8.0 |
12.0 |
10.0 |
3.0 |
13.5 |
9.0 |
13.5 |
10.5 |
EAG |
37 |
30.1.98 |
14.5 |
8.0 |
12.0 |
8.5 |
4.0 |
16.5 |
9.5 |
13.0 |
10.5 |
VA |
27 |
26.11.97 |
16.3 |
10.4 |
13.9 |
10.1 |
3.0 |
17.8 |
12.5 |
14.5 |
11.5 |
EAA |
46 |
15.3.98 |
14.5 |
10.5 |
12.0 |
10.0 |
6.0 |
17.6 |
15.7 |
13.2 |
11.2 |
JBV |
25 |
27.3.98 |
15.0 |
8.0 |
13.0 |
9.0 |
3.0 |
16.6 |
9.5 |
13.3 |
10.5 |
ABB |
39 |
29.6.98 |
14.0 |
11.0 |
13.0 |
11.0 |
3.0 |
15.5 |
12.5 |
14.0 |
12.0 |
CBG |
37 |
19.1.98 |
12.5 |
6.0 |
12.0 |
9.0 |
4.0 |
14.0 |
8.8 |
12.5 |
9.4 |
JBL |
25 |
7.5.98 |
13.7 |
9.0 |
11.5 |
10.0 |
4.0 |
16.3 |
11.5 |
13.5 |
12.0 |
JCB |
27 |
19.11.97 |
13.0 |
8.0 |
14.5 |
12.0 |
6.0 |
16.4 |
11.1 |
14.2 |
12.2 |
JJCA |
33 |
1.6.98 |
10.5 |
4.9 |
11.0 |
9.5 |
3.0 |
12.0 |
5.5 |
11.5 |
9.5 |
JCA |
32 |
4.2.98 |
14.0 |
10.0 |
10.0 |
9.0 |
4.0 |
15.9 |
12.0 |
12.2 |
10.5 |
ODV |
25 |
4.3.98 |
16.5 |
9.5 |
13.0 |
9.7 |
3.0 |
18.0 |
11.0 |
13.3 |
10.0 |
PDS |
22 |
10.6.98 |
14.4 |
8.3 |
11.0 |
7.8 |
3.0 |
15.8 |
9.0 |
11.6 |
8.3 |
AGM |
41 |
26.11.98 |
13.0 |
9.0 |
11.0 |
10.0 |
4.0 |
15.0 |
9.5 |
11.0 |
10.0 |
MGF |
32 |
29.9.97 |
12.5 |
5.5 |
12.5 |
10.0 |
4.0 |
14.5 |
8.0 |
13.0 |
10.0 |
AHM |
44 |
5.3.98 |
11.5 |
8.0 |
13.0 |
12.0 |
3.0 |
13.0 |
9.5 |
14.0 |
12.0 |
AAMP |
37 |
12.3.98 |
12.7 |
7.0 |
10.5 |
7.5 |
3.0 |
14.0 |
9.0 |
11.0 |
9.0 |
JLMO |
34 |
30.1.98 |
14.8 |
11.0 |
11.0 |
9.3 |
4.0 |
15.8 |
11.0 |
12.7 |
9.3 |
JAMV |
41 |
28.7.97 |
17.0 |
10.0 |
14.0 |
12.5 |
5.0 |
19.6 |
12.3 |
15.0 |
13.5 |
FOR |
8% |
9.11.97 |
12.5 |
7.0 |
10.0 |
9.0 |
5.0 |
14.5 |
11.0 |
11.0 |
10.5 |
ROM |
28 |
12.11.97 |
16.0 |
8.5 |
13.0 |
9.0 |
5.0 |
18.0 |
12.5 |
13.5 |
10.5 |
JPC |
33 |
16.1.98 |
13.7 |
7.2 |
12.3 |
10.1 |
3.0 |
16.7 |
8.7 |
13.1 |
10.9 |
JAPG |
29 |
4.11.97 |
10.0 |
8.0 |
12.0 |
10.0 |
6.0 |
13.5 |
11.5 |
13.0 |
11.0 |
FPR |
8% |
20.3.98 |
10.5 |
7.0 |
12.0 |
10.0 |
3.0 |
11.3 |
7.3 |
12.7 |
10.0 |
JPF |
42 |
23.3.98 |
13.0 |
7.0 |
13.0 |
10.0 |
3.0 |
14.5 |
8.5 |
13.0 |
10.5 |
AJRF |
26 |
28.11.97 |
14.0 |
9.0 |
13.0 |
9.0 |
4.0 |
16.0 |
10.7 |
13.0 |
10.0 |
ARR |
58 |
7.10.97 |
11.0 |
7.0 |
11.0 |
9.0 |
3.0 |
12.0 |
8.0 |
12.0 |
10.0 |
RRG |
25 |
25.11.97 |
14.5 |
11.0 |
11.0 |
10.0 |
3.0 |
15.0 |
12.4 |
11.7 |
10.8 |
CSM |
35 |
24.2.98 |
15.0 |
9.0 |
11.0 |
9.0 |
3.0 |
16.5 |
11.0 |
12.0 |
10.0 |
ASE |
35 |
20.3.98 |
12.5 |
7.5 |
11.5 |
9.0 |
4.0 |
14.5 |
9.5 |
12.5 |
10.5 |
ASPA |
42 |
7.11.97 |
14.0 |
7.5 |
12.0 |
9.0 |
4.0 |
16.0 |
9.5 |
13.0 |
10.5 |
SSF |
27 |
15.8.97 |
14.5 |
7.0 |
14.5 |
8.0 |
3.0 |
15.9 |
8.0 |
15.0 |
8.7 |
ISB |
22 |
23.9.97 |
11.5 |
7.5 |
11.0 |
9.5 |
4.0 |
13.5 |
10.2 |
11.3 |
10.3 |
FT |
53 |
19.11.97 |
14.5 |
10.0 |
13.0 |
10.0 |
3.0 |
16.0 |
11.5 |
13.5 |
10.5 |
EVC |
24 |
29.12.97 |
11.0 |
7.0 |
11.5 |
9.0 |
5.0 |
13.5 |
9.0 |
12.5 |
10.5 |
PV |
33 |
8.10.97 |
12.0 |
8.5 |
15.5 |
13.0 |
4.0 |
13.0 |
9.5 |
16.0 |
13.0 |
JSVS |
32 |
24.1.98 |
12.0 |
6.0 |
10.5 |
9.0 |
4.0 |
14.0 |
8.5 |
12.5 |
9.5 |
L-Erec1 = Length in Erection
initial
L-Flac1 = Length in Flaccidity
inicial
P-Erec1 = Perimeter in
Erection initial
P-Flac1 = Perimeter
in Flaccidity inicial
L-Erec2 = Length
in Erection final
L-Flac2 = Length in
Flaccidity final
P-Erec2 = Perimeter
in Erection final
P-Flac2 = Perimeter
in Flaccidity final
|